Le Lézard
Classified in: Health
Subjects: CCA, SLS, ACC

Interim Report 1 January - 30 June 2019: Q-linea


Launch preparations continue

STOCKHOLM, Sweden, July 18, 2019 /PRNewswire/ -- Second Quarter: 1 April?30 June 2019

Period: 1 January?30 June 2019

Significant events

in the second quarter of 2019

after the end of the period

Comments by the CEO

Intensified partner discussions

The second quarter of 2019 was characterised by feedback from potential customers following our participation in various conferences, preparations for regulatory studies and, last but not least, intensified discussions with several possible partners for the upcoming launch of ASTar.

The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) is the most important annual conference for Q-linea. This year it was held in Amsterdam on 13?16 April. I am proud of the fantastic feedback we received at ECCMID on ASTar. The same can be said for our participation in the American Society for Microbiology (ASM) Microbe in San Francisco on 20?24 June.

We have received overwhelmingly positive feedback on our broad antibiotics panel, ASTar's flexible but simple workflow and how easy it is to start using. Potential customers in Europe and the US are equally positive, but in the US we are encountering a somewhat different customer group. Customers in the US have more automated operations and more 24-hour labs. They are especially appreciative of the simplicity and the fully automated workflow, and it is particularly gratifying to be receiving positive feedback on our development process from future customers. Since customers are already starting to plan their budgets in order to purchase the system next year, it has been important for us to be able to present the final design of our ASTar system.

When it comes to our regulatory studies, we achieved an important milestone in June when we submitted a pre-submission supplement to the US Food and Drug Administration (FDA), as planned. The supplement contained a detailed description of how we plan to design the US study and the specifics of the trial protocol and the ASTar system. We will have a meeting with the FDA in September to hear their views on the design of the study and we will thereafter adapt the study to meet their requirements. If everything goes according to plan, we should be able to start the study at the beginning of next year. Our goal is to obtain FDA approval to market and sell the system next year.

I am happy to be leading the company and following its progress. We are methodically working through our goals and the impressive work that has been carried out throughout the company is now being reflected in our discussions with potential sales partners. These discussions intensified during the quarter and are now being conducted with some of the most attractive companies in the market. I look forward to our future partnership agreements with a sense of anticipation and optimism.

To sum up, the feedback we are receiving both from potential customers and in discussions with possible partners is incredibly motivating in our continued work to prepare ASTar for approval and market launch next year. I hope and believe that Q-linea's shareholders share our enthusiasm.

Jonas Jarvius, President

This report has been prepared in a Swedish original and an English translation. In the event of any discrepancies between the two, the Swedish version is to apply.

This interim report has not been reviewed by the company's auditor. 

Presentation

Q-linea invites investors, analysts and the media to an audiocast and teleconference (in English) today, 18 July, at 1:00 to 2:00 p.m. (CET). President Jonas Jarvius and CFO Anders Lundin will present Q-linea, com-ment on the interim report for the January to June 2019 period and respond to questions.

Webcast: https://tv.streamfabriken.com/q-linea-q2-2019 

Telephone number for the teleconference: SE: +46851999383 UK: +443333009262 US: +16467224956


Upcoming reporting dates

 

7 November 2019

Interim report, Q3

January to September 2019




13 February 2020

Year-end report, Q4

January to December 2019 




Week of 13 April 2020     

Annual Report 2019       

 January to December 2019




7 May 2020

Interim report, Q1

 January to March 2020




16 July 2020

Interim report, Q2

January to June 2020

 

5 November 2020

 

Interim report, Q3

January to September 2020 


About the company

Q-linea AB (publ)

Corporate Registration Number: 556729-0217
Registered office:
Uppsala
www.qlinea.com

Contact: Dag Hammarskjölds väg 52 A
E-mail: contact@qlinea.com  
SE-752 37 Uppsala, Sweden
Tel: +46-18-444-3610

For questions about the report, contact:
Jonas Jarvius, President
Tel: +46-70-323-7760
E-mail: jonas.jarvius@qlinea.com

Anders Lundin
Tel: +46-70-600-1520
E-mail: anders.lundin@qlinea.com

This information is information that Q-linea AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 18 July 2019 at 7:30 a.m. CET. 

About Q-linea

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTartm is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/q-linea/r/interim-report-1-january---30-june-2019,c2865282

The following files are available for download:

https://mb.cision.com/Main/17731/2865282/1079003.pdf

The full report (PDF)

https://mb.cision.com/Public/17731/2865282/9516d8c1b722d019.pdf

Press release (PDF)

 


These press releases may also interest you

at 18:10
TALTZ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually today at the European Congress of Rheumatology 2020 (EULAR). Eli Lilly and Company shared...

at 17:47
The U.S. Food and Drug Administration today continued to take action in the ongoing response to the COVID-19 pandemic: The FDA issued an updated FDA COVID-19 Response At-A-Glance Summary that provides a quick look at facts, figures and highlights of...

at 17:30
The "Bioresorbable Medical Material Market to 2027 - Global Analysis and Forecasts by Product Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering. The bioresorbable medical material market was valued at US$...

at 17:26
The healthcare system in the Commonwealth of Dominica was not strained by the pandemic, with the government managing to contain the spread of the virus from the onset, recording zero deaths and only 16 fully recovered cases. Nonetheless, the...

at 17:25
Since the week of March 12, the Ontario Health Coalition has been tracking all people who have been infected with COVID-19 in outbreaks in health care settings including hospitals, long-term care, retirement homes, public health units, clinics and...

at 17:15
The public has been made aware of the number of COVID-19 deaths and reported cases that have occurred since the beginning of the current pandemic; however, the number of unreported cases has not been widely known or publicized. Recently, the Centers...



News published on 18 july 2019 at 02:13 and distributed by: